NASDAQ: APYXApyx Medical Corp Stock
$4.11-0.10 (-2.38%)
Updated Jun 18, 2026
APYX Price
$4.11
Fair Value Price
-$4.07
Market Cap
$172.10M
52 Week Low
$1.59
52 Week High
$5.08
P/E
-18.68x
P/B
13.41x
P/S
2.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$55.90M
Earnings
-$9.17M
Gross Margin
63.2%
Operating Margin
-5.77%
Profit Margin
-16.4%
Debt to Equity
3.89
Operating Cash Flow
-$8M
Beta
1.28
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
APYX Overview
Apyx Medical Corporation, an energy technology firm established in 1982 and headquartered in Clearwater, Florida, focuses on the development, manufacturing, and global sale of medical devices for both the aesthetic and surgical fields. The company operates through two main divisions: Advanced Energy and Original Equipment Manufacturing (OEM). Among its key innovations is the Helium Plasma Generator, which delivers a controlled combination of RF energy and helium to precisely cut, coagulate, and ablate soft tissue in open and laparoscopic surgical procedures. For the cosmetic surgery market, Apyx Medical offers its Renuvion product line, enabling plastic surgeons and other aesthetic practitioners to apply targeted heat for desired patient outcomes. Concurrently, the J-Plasma brand caters specifically to the hospital surgical sector. Furthermore, the company designs, produces, and sells disposable hand pieces, alongside OEM generators and their related accessories. The entity was previously known as Bovie Medical Corporation, changing its name to Apyx Medical Corporation in January 2019.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APYX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
APYX
Ranked#30 of 93
Ranked#30 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $38.68 | A | |
| $26.62 | A |
Be the first to know about important APYX news, forecast changes, insider trades & much more!
APYX News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APYX ($4.11) is overvalued by 201.1% relative to our estimate of its Fair Value price of -$4.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
APYX ($4.11) is not significantly undervalued (201.1%) relative to our estimate of its Fair Value price of -$4.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APYX due diligence checks available for Premium users.
Valuation
APYX fair value
Fair Value of APYX stock based on Discounted Cash Flow (DCF)
Price
$4.11
Fair Value
-$4.07
Undervalued by
201.10%
APYX ($4.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APYX ($4.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.68x
Industry
20.08x
Market
9.47x
APYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.41x
Industry
2.95x
APYX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APYX's financial health
Profit margin
Revenue
$12.5M
Net Income
-$2.1M
Profit Margin
-16.9%
APYX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
APYX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.0M
Liabilities
$49.9M
Debt to equity
3.89
APYX's short-term assets ($54.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APYX's short-term assets ($54.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APYX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$572.0k
Investing
-$60.0k
Financing
$83.0k
APYX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APYX vs Medical Device Stocks
Apyx Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.